Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRFY7I)

Drug Name

ICA-17043 Drug Info

Synonyms

Senicapoc; 289656-45-7; 2,2-bis(4-fluorophenyl)-2-phenylacetamide; UNII-TS6G201A6Q; TS6G201A6Q; 2,2-BIS(4-FLUOROPHENYL)-2-PHENYL-ACETAMIDE; AK-79332; Senicapoc (USAN); Bis(4-fluorophenyl)phenylacetamide; Senicapoc [USAN:INN]; ICA 17043; C20H15F2NO; PubChem19381; 4-Fluoro-alpha-(4-fluorophenyl)-alpha-phenylbenzeneacetamide; AC1Q4NLN; AC1L50IL; CHEMBL405821; SCHEMBL1443805; GTPL2331; CTK4G2492; DTXSID60276906; SCTZUZTYRMOMKT-UHFFFAOYSA-N; MolPort-019-996-128; BCP14507; ACT06676; ZINC3816408; KS-00000XJ3; BBL102413; STL556215; Senicapoc

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Phase 2	[1]
Constitutional neutropenia	4B00.0	Discontinued in Phase 2	[2]

Cross-matching ID

PubChem CID: 216327
CAS Number: CAS 289656-45-7
TTD Drug ID: DMRFY7I

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Calcium-activated potassium channel (KCN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chlorzoxazone	DMCYVDT	Acute pain	MG31	Approved	[5]
Charybdotoxin	DMKN345	Scorpion envenoming syndrome	8D43	Approved	[6]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one	DMKMH5L	Discovery agent	N.A.	Investigative	[7]
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	DMQEJVU	Conjunctival fibrosis	9A61.3	Investigative	[7]
4-fluorophenyl-2,2-diphenylacetamide	DMI03KV	Discovery agent	N.A.	Investigative	[3]
N-methyl-2,2,2-triphenylacetamide	DMQGRMO	Discovery agent	N.A.	Investigative	[3]
TRIPHENYLMETHANAMINE	DM3CQIZ	Discovery agent	N.A.	Investigative	[3]
N,N-dimethyl-2,2,2-triphenylacetamide	DM9XZJN	Discovery agent	N.A.	Investigative	[3]
(2-fluorophenyl)-(4-fluorophenyl)phenylacetamide	DMFV76H	Discovery agent	N.A.	Investigative	[3]
2,2,2-tris-(3-fluorophenyl)-acetamide	DMJXAF7	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Calcium-activated potassium channel KCa3.1 (KCNN4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP0819	DM6HJ3V	Fibromyalgia	MG30.01	Phase 2	[8]
EBIO	DMPKI0N	Discovery agent	N.A.	Investigative	[9]
DC-EBIO	DM2T5OV	Discovery agent	N.A.	Investigative	[10]
1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole	DMQEJVU	Conjunctival fibrosis	9A61.3	Investigative	[11]
SKA-121	DMBL7YN	Discovery agent	N.A.	Investigative	[12]
PMID15603962Crac-16	DMN5LZQ	Discovery agent	N.A.	Investigative	[13]
SKA-31	DMX34F1	Discovery agent	N.A.	Investigative	[14]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium-activated potassium channel (KCN)	TTMNI76	NOUNIPROTAC	Inhibitor	[3]
Calcium-activated potassium channel KCa3.1 (KCNN4)	TT7M9I6	KCNN4_HUMAN	Modulator	[4]

------------------------------------------------------------------------------------

References

1	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2331).
3	Novel inhibitors of the Gardos channel for the treatment of sickle cell disease. J Med Chem. 2008 Feb 28;51(4):976-82.
4	Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.Expert Opin Investig Drugs.2009 Feb;18(2):231-9.
5	Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6.
6	Reversible inhibition of the platelet procoagulant response through manipulation of the Gardos channel. Blood. 2006 Oct 1;108(7):2223-8.
7	Inhibitors of potassium channels KV1.3 and IK-1 as immunosuppressants. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2299-304.
8	Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. J Pain Res. 2020 Dec 10;13:3355-3369.
9	Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
10	Benzimidazolone activators of chloride secretion: potential therapeutics for cystic fibrosis and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2001 Feb;296(2):600-11.
11	Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 2003 Sep 2;108(9):1119-25.
12	New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Mol Pharmacol. 2014 Sep;86(3):342-57.
13	IKCa-channel blockers. Part 2: discovery of cyclohexadienes. Bioorg Med Chem Lett. 2005 Jan 17;15(2):401-4.
14	Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol. 2009 Feb;75(2):281-95.